XORTX starts GMP manufacturing for XORLO to support XRX-OXY-102 gout trial
XRTX•GMP manufacturing launched for XORLO to support gout study
XORTX launched GMP manufacturing of XORLO, its oxypurinol formulation, to supply the planned two-part XRX-OXY-102 gout study.
The program advances based on prior supportive clinical results already presented, alongside FDA discussions.
Production covers drug substance and commercial-scale tablets intended to match potential US marketing-approval material.
Validation and stability work is expected to support a future FDA marketing application.
